Τόμος 11 (1997) – Τεύχος 1 – Άρθρο 4 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 11 (1997) – Issue 1 – Article 4 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

1. Molecular Endocrinology Laboratory and Prostate Cancer Clinic, Research Center, Pavillon C.H.U.L, Department of Physiology-Endocrinology, and Obstetrics-Gynecology, Laval University, Quebec, Canada

2. Department of Physiology, Medical School of Athens, 75 Micras Asias, Goudi, Athens 115 27, Greece

3.        Sobin LH: Incidence of prostatic carcinoma. Scand. J. Urol. Nephrol. Suppl. 55: 7-8 (1980)

4.        Huggins C, Hodges CV: Studies on prostate cancer. The effect of castration, of estrogen, and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res. 1: 193-198 (1941)

5.        Nesbitt R, Baum WC: Endocrinexontrol of prostatic carci-noma. JAMA 143: 1317-1325 (1950)

6.        Schroder FH: Screening, early detection, and treatment of prostate cancer: a European view. Urology 46 (Suppl A): 62-70 (1995)

7.         Labrie F, Dupont A, Suburu R, Cusan L, Koutsilieris M, Gomez J-L, Lemay M: Optimized strategy for the detection of early stage, curable prostate cancer: the role of prescreening with prostate-specific antigen. Clin. Invest. Med. 16: 425-439 (1993)

8.        Koutsilieris M: Osteoblastic metastasis in advanced prostate cancer. Anticancer Res. 13: 443-450 (1993)

9.        Galasco CSB: Mechanisms of lytic and blastic metastatic disease of bone. Clin. Orthopaed. Rel. Res. 12: 20-27 (1982)

10.      Koutsilieris M: Skeletal metastasis in advanced prostate cancer: cell biology and therapy. Crit. Rev. Oncol. Hematol. 18: 51-64 (1995)

11.       Koutsilieris M, Dimopoulos MA, Doillon C, Sourla A, Reyes-Moreno C, Choki I: The molecular concept of prostate cancer. Cancer J. 9: 89-94 (1996)

12.      Koutsilieris M, Polychronakos C: Proteolytic activity against IGF-binding proteins involved in paracrine interactions prostate adenocarcinoma cells and osteoblasts. Anticancer Res. 12: 905-910 (1992)

13.      Koutsilieris M, Frenette G, Lazure C, Lehoux JG, Govindan MV, Polychronakos C: Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res. 13: 481-486 (1993)

14.      Koutsilieris M, Rabbani SA, Goltzman D: Selective os-teoblast mitogens can be extracted from prostatic tissue. Prostate 9: 109-115 (1986)

15.      Koutsilieris, M., S. A. Rabbani, and D. Goltzman. 1987. Effects of human prostatic mitogens on rat bone cells and fibroblasts. J. Endocr. 115: 447-454 (1987)

16.      Koutsilieris M, Rabbani SA, Bennett HPJ, Goltzman D: Characteristics of prostate-derived growth factors cells of the osteoblast phenotype. J. Clin. Invest. 80: 941-946 (1987)

17.       Koutsilieris M, Tolis G: Gonadotropin-releasing hormone agonistic analogues in the treatment of the advanced prostatic cancer. Prostate 4: 569-572 (1983)

18.      Koutsilieris M, Dupont A, Gomez J-L, Cusan L, Suburu R, Labrie F: Stratification of stage D2 prostatic cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormone treatment (GnRH-A plus flutamide). Anticancer Res. 14: 627-634 (1994)

19.      Labrie F: Endocrine therapy of prostate cancer: optimal form and timing. J. Clin. Endocrinol. Metab. 80: 1066-1071 (1995)

20.      Kozlowski JM, Ellis. WJ, Grayhack JT: Advanced prostatic carcinoma: early vs late endocrine therapy. In: (GL Andriole, WJ Catalona eds) The Urologic Clinics of North America, pp. 15-24, Pholadelphia, 1991

21.      Koutsilieris M, Faure N, Laroche B, Tolis G, Roberts G, Ackman CGD: Objective response and disease outcome in 59 patients with stage D2 prostatic carcinoma treated with either Buserelin or orchiectomy: disease aggressivity and its association with response and outcome. Urology 27: 221- 227 (1986)

22.      Koutsilieris M, Laroche B, Thabet M, Fradet Y: The as-sessment of disease aggressivity in stage D2 prostate cancer patients. Anticancer Res. 10: 333-336 (1990)

23.      Koutsilieris M, Sourla A, Pelletier G, Doillon C: Three-dimensional type I collagen gel system for the study of os-teoblastic metastases produced by metastastic prostate cancer. J. Bone Miner. Res. 9: 1823-1832 (1994)

24.      Koutsilieris M, Ackman CFD: Complete response of lung metastases caused by prostatic cancer after chronic administration of a gonadotropin-releasing hormone agonistic analogue, buserelin (HOE 766). Prostate 10. 19-24 (1987)

25.      Behrakis P, Koutsilieris M: Pulmonary metastases in prostate cancer: host tissue-tumor cell interactions and response to hormone therapy. Anticancer Res. 17: 1517-1518 (1997)

26.      McConkey DJ, Greene G, Pettaway CA: Apoptosis re-sistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res. 56: 5594-5599 (1996)

27.      Mertens WC, Stitt L, Porter AT: Strodium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship. Am. J. Clin. Oncol. 16: 238-242 (1993)

28.      Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332: 1393-1398 (1995)

29.      Gottlieb B, Trifiro M, Lumbroso R, Pinsky L: The androgen receptor gene mutations database. Nucleic Acids Res. 25: 158-162 (1997)

30.      Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J: Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 29: 53-158 (1996)

31.      Dupont A, Gomez J-L, Cusan L, Koutsilieris M, Labrie F: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol. 150: 908-913 (1993)

32.      Kyprianou N, Bains AK, Jacobs SC: Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. Prostate 25: 66-75 (1994)

33.      Furuya Y, Isaacs JT: Proliferation-dependent vs. independent programmed cell death of prostatic cancer cells involves distinct gene regulation. Prostate 25: 301-309 (1994)

34.      Kaighn ME, Shankar NK, Ohnuki Y, Lechner JF, JonesLW: Establishment and characterization of a human prostatic carcinoma cell lines (PC-3). Invest. Urol. 17: 16-23 (1979)

35.      Tilley WD, Wilson CM, Marcelli M, McPhaul MJ: Androgen receptor gene expression in human prostate car-cinoma cell lines. Cancer Res. 50: 5382-5386 (1990)

36.      Kyprianou N, Isaacs JT: “Thyminetess” death in androgen independent prostatic cancer cells. Btochem. Biophys. Res. Commun. 165: 73-81 (1989)

37.      Pollack A, Ciancio G: Cell cycle phase-specific analysis of cell viability using Hoechst 33342 and propidium iodide after ethanol preservation. In: Flow cytometry (Z Darzynkiewicz. HA Crissman eds), pp. 19-24, Academic Press, San Diego, 1991

38.      Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Virudachalam S, Yandell DW, Weichselbaum RR: Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J. Surg. Oncol. 46: SI- 36 (1991)

39.      Tilley WD, Bentel JM, Aspinall JO, Hall RE, Horsfall DJ: Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids 60: ISO-186 (1995)

40.      Isaacs W.B, Carter BS, Ewing CM: Wild-type p53 sup-presses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 51: 4716-4720 (1991)

41.      Borner M.M, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E: Drug-induced apoptosis is not necessarily dependent on macromolecule synthesis or proliferation in the p53 negative human prostate cancer cell line PC-3. Cancer Res. 55: 2122-2128 (1995)

42.      Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA: Interference with DNA unwinding by doxorubicin in MCF-7 breast tumor cells. Mol. Pharmacol. 46: 649- 656 (1994)

43.      Goldenberg GJ, Wang H, Blair GW: Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA singled- and double-strand breakage in cloned cell lines of adriamycin-sensitive and resistant P388 leukemia. Cancer Res. 46: 2978-2983 (1986)

44.      Doroshow JH: Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem. Biophys. Res. Commun. 135: 330-335 (1986)

45.      Fornari FA.Jr, Jarvis WD, Grant S, Orr MS, Randolph JK, White FKH, Mumaw VR, Lovings ET, Freeman RH, Gewirtz DA: Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Ceil Growth & Differ. 5: 723-733 (1994)

46.      Boulanger J, Reyes-Moreno C, Koutsilieris M: Mediation of the glucocorticoid receptor (GR) function by the activation of latent transforming growth factor beta 1 in MG-63 osteoblasts-like osteosarcoma cells, int. J. Cancer 62: 692-697 (1995)

47.      Sourla A, Doillon C, Koutsilieris M: Three-dimensional type I collagen gel system containing MG-63 osteoblasts-like cells as a model for studying local bone reaction caused by metastatic cancer cells. Anticancer Res. 16: 2773-2780 (1996)

48.      Janvier R, Sourla A, Koutsilieris M, Doillon C: Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system. Anticancer Res. 17: 1551-1558 (1997)

49.      Borsellino N, Belldegrun A, Bonavida B: Endogenous in-terleukin 6 is a resistance factor for cis-diaminedichloroplatinum and etoposidemediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 55: 4633-4639 (1995)

50.      P’arrizas M, Leroith D: Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-x. gene product. Endocrinology 138: 1355-1358 (1997)

51.      Reyes-Moreno C, Frenette G, Boulanger J, Lavergne E, Govindan MV, Koutsilieris M: Mediation of glucocorticoid re-ceptor function by transforming growth factor beta 1 expression in human PC-3 prostate cancer cells. Prostate 26: 260-269 (1995)

52.      Reyes-Moreno C, Koutsilieris M: Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton. Clin. Exp. Met. 15: 205-217 (1997)

53.      Landstrom M, Damber J-E, Bergh A: Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased cell death rate. Cancer Res. 54: 4281-4284 (1994)

54.      Oltvai ZN, Korsmeyer SJ: Checkpoints of dueling dimmers foil death wishes. Cell 79: 189-192 (1996)

55.      Gajewski TF, Thompson CB: Apoptosis meets signal transduction: elimination of a BAD influence. Cell 86•. 589-592 (1996)

56.      Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ: Serine phosphorylation of death agonist Bad in response to survival factor results in binding 10 14-3-3 not Bcl-xL. Cell 87: 619-628 (1996)